Key facts
- It has raised $3.1M.
- Notable investors include Arcano Partners, CIMTI, CRAASH Barcelona, Decelera Ventures, Fundo Bem Commons FCR — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Flomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Flomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Flomics
Operator of a molecular diagnostics company intended to improve clinical practice development of a multi-disease detection test from a standard blood sample. The company offers a liquid biopsy solution that uses a simple blood draw to analyze circulating ribonucleic acid (RNA) molecules which can be done through their machine learning model to interpret and identify disease signatures, enabling healthcare providers with timely intervention before symptoms appear.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2018
- Employees
- 25
- Website
- flomics.com/
- Ownership
- Privately Held (backing)
Flomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Flomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Flomics in its N-PORT filings yet. We sweep new filings monthly.